Topic

Articles

Data from past clinical trials has provided researchers with a good starting point to create more ECAs.

Pandemic has brought new sense of awareness to respiratory diseases and clinops.

Director, Life Sciences, Linguamatics, an IQVIA company

Natural language processing can help simplify protocols of the past, as evidenced by a recent Novartis initiative. 

Kenneth Getz is a senior research fellow at the Tufts Center for the Study of Drug Development.

Study uncovers pre-pandemic deviation levels.

Addressing sources of tension on differentiating types of data.

SVP, Clinical Pharmacology & Translational Medicine

Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.

A look at the prevalence of placebo response in clinical trials and how advanced solutions can mitigate the risk it poses to drug development.

Implementing new strategies with the use of patient-reported outcomes.

Insights from studies on advisory boards and participation burden.

Increased use of remote assets will showcase new endpoints derived from digital health technologies.